drugset / Trial / NCT02772003
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
Phase 1
Active not recruiting
33 enrolled
National Cancer Institute (NCI)
Inovio Pharmaceuticals · collab
NaSingle-groupSingle-blindPrevention
Summary
This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.
Timeline
- Start
- 2016-06-06
- Primary completion
- 2020-03-04
- Completion
- 2027-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO-8000 | Unknown | — | Intramuscular |
| Subject | Rocakinogene Sifuplasmid | Vaccine | — | Intramuscular |